Compare Stocks

Date Range: 

 AlkermesPacira BioSciencesArvinasMorphoSysOrganogenesis
SymbolNASDAQ:ALKSNASDAQ:PCRXNASDAQ:ARVNNASDAQ:MORNASDAQ:ORGO
Price Information
Current Price$22.34$60.72$61.29$20.35$17.92
52 Week RangeHoldBuyBuyHoldBuy
MarketRank™
Overall Score1.22.31.70.31.0
Analysis Score1.04.34.50.01.5
Community Score2.82.92.41.42.7
Dividend Score0.00.00.00.00.0
Ownership Score1.70.01.70.00.8
Earnings & Valuation Score0.64.40.00.00.0
Analyst Ratings
Consensus RecommendationHoldBuyBuyHoldBuy
Consensus Price Target$22.00$78.58$113.15N/A$17.50
% Upside from Price Target-1.52% downside29.42% upside84.62% upsideN/A-2.34% downside
Trade Information
Market Cap$3.58 billion$2.67 billion$3.01 billion$2.68 billion$2.30 billion
Beta1.251.272.141.031.84
Average Volume1,382,726476,391456,58855,241827,913
Sales & Book Value
Annual Revenue$1.17 billion$421.03 million$42.98 million$80.43 million$260.98 million
Price / Sales3.066.3569.8633.298.80
Cashflow$0.60 per share$1.43 per shareN/AN/AN/A
Price / Cash37.5242.56N/AN/AN/A
Book Value$6.89 per share$8.51 per share$6.72 per share$3.49 per share$0.59 per share
Price / Book3.247.149.125.8330.37
Profitability
Net Income$-196,620,000.00$-11,020,000.00$-70,290,000.00$-115,380,000.00$-40,450,000.00
EPS$0.07$0.86($2.13)($0.91)($0.42)
Trailing P/E RatioN/A21.38N/A96.91N/A
Forward P/E Ratio319.1421.08N/AN/AN/A
P/E Growth12.740.82N/AN/AN/A
Net Margins-6.28%29.95%-403.77%8.76%-1.61%
Return on Equity (ROE)9.35%10.71%-46.99%4.51%-10.03%
Return on Assets (ROA)5.50%4.88%-35.34%2.25%-2.22%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity Ratio0.25%0.78%0.01%N/A1.54%
Current Ratio2.71%7.63%6.53%5.02%1.95%
Quick Ratio2.39%6.84%6.53%4.93%1.50%
Ownership Information
Institutional Ownership Percentage97.30%N/A75.68%3.06%4.62%
Insider Ownership Percentage4.49%5.80%10.99%N/A57.20%
Miscellaneous
Employees2,245624179615910
Shares Outstanding160.45 million44.03 million48.99 million131.56 million128.21 million
Next Earnings Date8/4/2021 (Estimated)8/5/2021 (Estimated)8/3/2021 (Estimated)8/4/2021 (Estimated)8/9/2021 (Estimated)
OptionableOptionableOptionableNot OptionableNot OptionableNot Optionable
SourceHeadline
Organogenesis Holdings Inc. (ORGO) CEO Gary Gillheeney on Q1 2021 Results - Earnings Call Transcript - Seeking AlphaOrganogenesis Holdings Inc. (ORGO) CEO Gary Gillheeney on Q1 2021 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - May 11 at 7:11 PM
Organogenesis Holdings Inc (ORGO) Q1 2021 Earnings Call Transcript - Motley FoolOrganogenesis Holdings Inc (ORGO) Q1 2021 Earnings Call Transcript - Motley Fool
fool.com - May 11 at 7:11 PM
Where Does Organogenesis Holdings Inc (ORGO) Stock Fall in the Drug Manufacturers - Specialty & Generic Field After It Has Fallen -14.71% This Week? - InvestorsObserverWhere Does Organogenesis Holdings Inc (ORGO) Stock Fall in the Drug Manufacturers - Specialty & Generic Field After It Has Fallen -14.71% This Week? - InvestorsObserver
investorsobserver.com - May 11 at 2:10 PM
Form 10-Q Organogenesis Holdings For: Mar 31 - StreetInsider.comForm 10-Q Organogenesis Holdings For: Mar 31 - StreetInsider.com
streetinsider.com - May 11 at 2:10 PM
Organogenesis (NASDAQ:ORGO)  Shares Down 6.8%  After Analyst DowngradeOrganogenesis (NASDAQ:ORGO) Shares Down 6.8% After Analyst Downgrade
americanbankingnews.com - May 11 at 12:27 PM
Organogenesis (NASDAQ:ORGO) Given New $26.00 Price Target at SVB LeerinkOrganogenesis (NASDAQ:ORGO) Given New $26.00 Price Target at SVB Leerink
americanbankingnews.com - May 11 at 11:18 AM
CORRECTING and REPLACING – Organogenesis Holdings Inc. Reports First Quarter 2021 Financial Results - Yahoo FinanceCORRECTING and REPLACING – Organogenesis Holdings Inc. Reports First Quarter 2021 Financial Results - Yahoo Finance
finance.yahoo.com - May 11 at 9:10 AM
Organogenesis Holdings Inc (ORGO) Q1 2021 Earnings Call TranscriptOrganogenesis Holdings Inc (ORGO) Q1 2021 Earnings Call Transcript
finance.yahoo.com - May 11 at 9:10 AM
Organogenesis (ORGO) Surpasses Q1 Earnings and Revenue Estimates - Yahoo FinanceOrganogenesis (ORGO) Surpasses Q1 Earnings and Revenue Estimates - Yahoo Finance
finance.yahoo.com - May 11 at 1:36 AM
Organogenesis Holdings Posts Q1 EPS Of $0.07 - CMLViz.com - CML NewsOrganogenesis Holdings Posts Q1 EPS Of $0.07 - CMLViz.com - CML News
cmlviz.com - May 10 at 8:35 PM
Organogenesis (ORGO) Surpasses Q1 Earnings and Revenue Estimates - NasdaqOrganogenesis (ORGO) Surpasses Q1 Earnings and Revenue Estimates - Nasdaq
nasdaq.com - May 10 at 8:35 PM
Organogenesis Holdings: Q1 Earnings Insights - BenzingaOrganogenesis Holdings: Q1 Earnings Insights - Benzinga
benzinga.com - May 10 at 8:35 PM
Organogenesis: Q1 Earnings Snapshot - San Francisco ChronicleOrganogenesis: Q1 Earnings Snapshot - San Francisco Chronicle
sfchronicle.com - May 10 at 8:35 PM
CORRECTING and REPLACING – Organogenesis Holdings Inc. - GlobeNewswireCORRECTING and REPLACING – Organogenesis Holdings Inc. - GlobeNewswire
globenewswire.com - May 10 at 8:35 PM
Organogenesis Holdings Inc. Reports First Quarter 2021 Financial ResultsOrganogenesis Holdings Inc. Reports First Quarter 2021 Financial Results
finance.yahoo.com - May 10 at 8:35 PM
CORRECTING and REPLACING – Organogenesis Holdings Inc. Reports First Quarter 2021 Financial ResultsCORRECTING and REPLACING – Organogenesis Holdings Inc. Reports First Quarter 2021 Financial Results
finance.yahoo.com - May 10 at 8:35 PM
Organogenesis (ORGO) Surpasses Q1 Earnings and Revenue EstimatesOrganogenesis (ORGO) Surpasses Q1 Earnings and Revenue Estimates
finance.yahoo.com - May 10 at 8:35 PM
Organogenesis (NASDAQ:ORGO) Updates FY 2021 Earnings GuidanceOrganogenesis (NASDAQ:ORGO) Updates FY 2021 Earnings Guidance
americanbankingnews.com - May 10 at 5:22 PM
Diabetic Foot Ulcer Therapeutic Market : Information, Figures And Analytical Insights 2021-2026-B. Braun Melsungen AG, Smith & Nephew, Inc., Organogenesis, Inc. – The Shotcaller - The ShotcallerDiabetic Foot Ulcer Therapeutic Market : Information, Figures And Analytical Insights 2021-2026-B. Braun Melsungen AG, Smith & Nephew, Inc., Organogenesis, Inc. – The Shotcaller - The Shotcaller
theshotcaller.net - May 10 at 10:35 AM
Organogenesis Appoints Jon Giacomin to Board of Directors - GlobeNewswireOrganogenesis Appoints Jon Giacomin to Board of Directors - GlobeNewswire
globenewswire.com - May 10 at 10:35 AM
Organogenesis Showcases Latest Advanced Wound Care - GlobeNewswireOrganogenesis Showcases Latest Advanced Wound Care - GlobeNewswire
globenewswire.com - May 8 at 8:50 AM
Zacks Investment Research Lowers Organogenesis (NASDAQ:ORGO) to HoldZacks Investment Research Lowers Organogenesis (NASDAQ:ORGO) to Hold
marketbeat.com - May 8 at 2:26 AM
Earnings Outlook for Organogenesis Holdings - BenzingaEarnings Outlook for Organogenesis Holdings - Benzinga
benzinga.com - May 7 at 1:02 PM
Organogenesis Showcases Latest Advanced Wound Care Innovations and Research at SAWC Spring | WHS 2021 Virtual Meeting - Yahoo FinanceOrganogenesis Showcases Latest Advanced Wound Care Innovations and Research at SAWC Spring | WHS 2021 Virtual Meeting - Yahoo Finance
finance.yahoo.com - May 6 at 10:01 PM
Organogenesis Showcases Latest Advanced Wound Care Innovations and Research at SAWC Spring | WHS 2021 Virtual MeetingOrganogenesis Showcases Latest Advanced Wound Care Innovations and Research at SAWC Spring | WHS 2021 Virtual Meeting
finance.yahoo.com - May 6 at 10:01 PM
05:00 ET 2020 STELLARIS Award Recipient Announced - PRNewswire05:00 ET 2020 STELLARIS Award Recipient Announced - PRNewswire
prnewswire.com - May 6 at 7:00 AM
Zacks Investment Research Downgrades Organogenesis (NASDAQ:ORGO) to HoldZacks Investment Research Downgrades Organogenesis (NASDAQ:ORGO) to Hold
marketbeat.com - April 17 at 3:20 AM
DateCompanyBrokerageAction
5/5/2021AlkermesHC WainwrightBoost Price Target
4/26/2021AlkermesMizuhoBoost Price Target
12/11/2020AlkermesSVB LeerinkBoost Price Target
10/7/2020AlkermesJPMorgan Chase & Co.Reiterated Rating
9/30/2020AlkermesBank of AmericaLower Price Target
7/30/2020AlkermesThe Goldman Sachs GroupDowngrade
4/29/2020AlkermesPiper SandlerLower Price Target
4/29/2020AlkermesStifel NicolausLower Price Target
4/2/2020AlkermesMorgan StanleyLower Price Target
2/14/2020AlkermesCowenReiterated Rating
5/11/2021Pacira BioSciencesNorthland SecuritiesLower Price Target
5/10/2021Pacira BioSciencesBMO Capital MarketsLower Price Target
4/15/2021Pacira BioSciencesBerenberg BankInitiated Coverage
2/26/2021Pacira BioSciencesBarclaysBoost Price Target
1/8/2021Pacira BioSciencesNeedham & Company LLCBoost Price Target
1/6/2021Pacira BioSciencesRoyal Bank of CanadaBoost Price Target
11/2/2020Pacira BioSciencesWedbushLower Price Target
9/30/2020Pacira BioSciencesJefferies Financial GroupBoost Price Target
8/14/2020Pacira BioSciencesTruistBoost Price Target
4/27/2021ArvinasTruist SecuritiesInitiated Coverage
4/21/2021ArvinasNorthern Trust Capital MarketsInitiated Coverage
3/30/2021ArvinasCantor FitzgeraldBoost Price Target
1/19/2021ArvinasOppenheimerBoost Price Target
12/15/2020ArvinasCitigroup Inc. 3% Minimum Coupon Principal Protected Based Upon RussellBoost Price Target
12/15/2020ArvinasSmith Barney CitigroupBoost Price Target
12/15/2020ArvinasRoth CapitalBoost Price Target
4/8/2021MorphoSysDeutsche Bank AktiengesellschaftReiterated Rating
5/12/2020MorphoSysHSBCUpgrade
11/27/2019MorphoSysGuggenheimInitiated Coverage
11/5/2018MorphoSysPiper Jaffray CompaniesInitiated Coverage
3/12/2021OrganogenesisCredit Suisse GroupBoost Price Target
1/14/2021OrganogenesisBTIG ResearchBoost Price Target
(Data available from 5/11/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.